Overexpression of LaMDR2, a novel multidrug resistance ATP-binding cassette transporter, causes 5-fluorouracil resistance in Leishmania amazonensis11The sequence data reported in this paper have been submitted to the DDBJ database under the accession number AB008469.  by Katakura, Ken et al.
Overexpression of LaMDR2, a novel multidrug resistance ATP-binding
cassette transporter, causes 5-£uorouracil resistance in
Leishmania amazonensis1
Ken Katakuraa;, Hiroshi Fujiseb, Keiichi Takedab, Osamu Kanekoc, Motomi Toriic,
Mamoru Suzukia, Kwang Poo Changd, Yoshihisa Hashiguchie
aDepartment of Parasitology, Gunma University Graduate School of Medical Science, Maebashi, Gunma 371-8511, Japan
bLaboratory of Pathobiochemistry, School of Veterinary Medicine, Azabu University, Sagamihara, Kanagawa 229-8501, Japan
cDepartment of Molecular Parasitology, Ehime University School of Medicine, Shigenobu-cho, Ehime 791-0295, Japan
dDepartment of Microbiology and Immunology, UHS/Chicago Medical School, North Chicago, IL 60064, USA
eDepartment of Parasitology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
Received 8 January 2004; revised 4 February 2004; accepted 4 February 2004
First published online 13 February 2004
Edited by Felix Wieland
Abstract The ATP-binding cassette (ABC) proteins play an
important role in drug resistance and detoxi¢cation in various
organisms. Here we isolated LaMDR2, a new member of the
multidrug resistance (MDR) subfamily of ABC proteins in
Leishmania amazonensis. LaMDR2 exhibited 47% amino acid
identity to its most closely related protein, LaMDR1, which was
previously isolated from the same species. Promastigotes that
overexpressed LaMDR2 showed signi¢cant resistance to 5-£uo-
rouracil (5-FU), but not to LaMDR1 substrates. Expression of
LaMDR2 in the transfectants was relatively higher in the log
phase than the stationary phase, and a lower accumulation of
[3H]5-FU was observed in the log-phase cells. These results
suggest that LaMDR2 is involved in extrusion of xenobiotics,
but functionally di¡erent from LaMDR1.
5 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Protozoan parasites of the genus Leishmania cause a wide
spectrum of human diseases ranging from mild cutaneous
leishmaniasis to fatal visceral leishmaniasis (kala-azar). Leish-
maniasis is endemic in 88 countries, and the overall prevalence
is estimated at 12 million [1]. The primary control measure
against leishmaniasis is treatment of patients with pentavalent
antimonial drugs, although the precise mechanism of action of
antimonials is unknown. However, the emergence of anti-
mony-resistant Leishmania parasites is evident in di¡erent en-
demic areas [2^4]. Studies on the mechanisms of drug resis-
tance are thus crucial for a more rational use of drugs to
minimize or overcome resistance. Resistance in clinical cases
is not easily de¢ned in biological terms, but studies on para-
sites selected for drug resistance in the laboratory have re-
vealed that several mechanisms are involved in drug resis-
tance, including a decrease in drug uptake, active drug
extrusion, loss of drug activation, and alteration of drug tar-
gets [5^7].
The ATP-binding cassette (ABC) protein superfamily is one
of the largest families found in both eukaryotic and prokary-
otic cells [8^12]. In humans, the 48 known ABC proteins are
classi¢ed into seven distinct subfamilies and implicated in a
number of serious diseases [12]. Multidrug resistance protein
(MDR1) in the ABCB (MDR/TAP) subfamily and multidrug
resistance-associated protein 1 (MRP1) in the ABCC (CFTR/
MRP) subfamily are the most extensively studied in relation
to drug resistance. MDR1 transports a wide variety of struc-
turally unrelated anticancer drugs in addition to physiological
substrates, including ions, phospholipids, steroids, amino
acids and peptides by coupling drug/lipid e¥ux with energy
derived from the hydrolysis of ATP [13]. MRP1 transports
organic anions and drugs conjugated to glutathione, glucuro-
nate or sulfate [5].
In Leishmania, MDR (ABCB), MRP (ABCC) and ABCA
subfamily genes have been identi¢ed and characterized
[6,7,14], and 25 ABC transporter family-like proteins are listed
in the recent Leishmania major Gene DB, (http://www.gened-
b.org/genedb/leish). Previously, we isolated the Leishmania
amazonensis MDR1 gene, which shared 78% and 91% amino
acid identity with LeMDR1 and LdMDR1 from di¡erent
Leishmania species, respectively [15^17]. Overexpression of
these leishmanial MDR1 genes in their transfectants conferred
resistance to certain anticancer drugs, including vinblastine,
although their physiological functions remain unknown. Anal-
ysis of arsenite-resistant Leishmania tarentolae led to the dis-
covery of the LtPGPA gene, the ¢rst eukaryotic MRP-like
gene [18]. Overexpression of LtPGPA in the transfectants con-
ferred resistance to oxyanions, such as arsenite and antimony
[19]. The LtPGPA tagged with green £uorescent protein
(GFP) was shown to be located in the intracellular vesicular
membrane close to the £agellar pocket, suggesting that PGPA
confers resistance by sequestering metal-thiol conjugates into
intracellular vesicles [20]. Five other PGP subfamily proteins
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were identi¢ed in Leishmania, but MDR1 was the only MDR
subfamily protein reported [7].
In the present study, we report the isolation and character-
ization of the LaMDR2 gene in L. amazonensis, which en-
codes a new member of the MDR (ABCB) subfamily of
Leishmania ABC proteins. We found that overexpression of
the LaMDR2 gene in wild-type promastigotes conferred resis-
tance to 5-£uorouracil (5-FU), a £uoropyrimidine used in
cancer chemotherapy. A decreased accumulation of 5-FU
was observed in the transfectants that overexpressed
LaMDR2 proteins. These results suggest that MDR2 plays
a role in e¥ux of toxic compounds. Although 5-FU and vin-
blastine are not clinically used for treatment of leishmaniasis,
an understanding of the molecular mechanisms of drug resis-
tance mediated by ABC transporters in Leishmania will pro-
vide further insight into novel chemotherapeutic strategies
against this worldwide tropical disease.
2. Materials and methods
2.1. Growth study
Promastigotes of L. amazonensis (MPRO/BR/72/M1845, LV78)
were cultivated at 26‡C in Medium 199 supplemented with 15%
heat-inactivated fetal calf serum and 25 mM HEPES [21]. A growth
inhibition test was performed against anticancer drugs (vinblastine,
puromycin, doxorubicin and 5-FU), anti-leishmanial drugs (Pento-
stam0 and amphotericin B), anti-malarial reagents (chloroquine,
me£oquine and artesunate), heavy metals (sodium arsenite and
CdCl2), and nucleoside analogues (formycin B and tubercidin). These
chemicals were obtained from Sigma Chemicals (St Louis, MO,
USA), except for Pentostam (Wellcome Foundation, London, UK),
me£oquine and artesunate (Mepha, Aesch-Basel, Switzerland). Pro-
mastigotes were incubated in each well of a 96-well, £at-bottomed
microplate at a concentration of 2U105 cells/ml in a volume of 200
Wl in the presence of two-fold serial dilutions of the drug. The plates
were incubated at 26‡C for 4^5 days until control cultures without the
drug reached maximum growth [17]. The number of parasites in cul-
ture was counted using a hemocytometer. Growth curves of promas-
tigotes were also determined by measuring the absorbance for the
cultures at 600 nm [18]. The e¡ective concentrations of the drug,
de¢ned as concentrations at which parasite growth was inhibited by
50% (ED50), were calculated.
2.2. Cloning and sequencing
The sense (5P-GGCTCGTCGGGCTGCGGG/CAA-3P) and anti-
sense (5P-GTCCAGCGCC/TGAC/TGTCGCCTCG/ATC-3P) primers
were synthesized according to conserved amino acid residues
(GSSGCGK and DEATSALD) within the ABC region [17]. A poly-
merase chain reaction (PCR) product of 408 bp ampli¢ed from L.
amazonensis DNA was cloned into the SmaI site of pUC18 plasmid.
Two clones showed the same nucleotide sequence (136 amino acids),
which was 67% identical to the NH2-terminal ABC region of the
LdMDR1 gene [15]. One clone (LA10) was used as a probe to isolate
genomic counterparts from a VGEM-11 genomic library prepared
from L. amazonensis DNA. Thirteen phages (V-01 to V-13) were ob-
tained with the LA10 probe. Four SacI fragments (0.34, 1, 2.5 and 6
kb) of V-13 phage were subcloned into pUC19 or pBluescript plasmid.
The 1-kb SacI fragment containing the 5P region corresponding to the
NH2-terminal ABC region of the LdMDR2 gene was ¢rst sequenced
by a primer walking method. Finally, a total of 4526 nucleotides,
including 3801 nucleotides for an open reading frame from four
SacI fragments, were sequenced in both directions using a total of
27 primers that were designed according to the nucleotide sequences
determined in each sequencing process.
2.3. DNA constructs and transfection
An approximately 7.0-kb HindIII fragment of the V-13 phage was
subcloned into the pcDNA3 plasmid. To generate p6.5-LaMDR2/7,
the HindIII fragments were ligated to BamHI linker and inserted into
the BamHI site of the Leishmania-speci¢c expression vector p6.5,
which contained the N-acetylglucosamine-1-phosphate transferase
gene (nagt) as a selective marker for tunicamycin selection [22,23].
The entire LaMDR2 was ampli¢ed by PCR using the sense primer
(5P-GGGGGATCCATGTCCGCCGATAAAAAG-3P) and the anti-
sense primer (5P-AGCTGGATCCTCACGTCTGGGCTAGCTCC-
CA-3P). Both primers contained a BamHI site (indicated by bold
letters). The sense and antisense primers contained the start codon
(underlined) and the stop codon (doubly underlined) of LaMDR2,
respectively. The PCR products were digested with BamHI and cloned
into the BamHI site of p6.5 to generate p6.5-LaMDR2/3.8. These
expression vectors were transfected into wild-type promastigotes by
electroporation [17]. Cells were then cultured in the presence of tuni-
camycin (Sigma) at 10 Wg/ml. Drug concentration was increased to 20
and 40 Wg/ml, and transfectant cell lines at each drug concentration
were obtained.
2.4. DNA and RNA manipulations
DNA extract (500 ng) was digested with di¡erent endonucleases
and blotted to a nylon membrane (Hybond-Nþ, Amersham) in
20USSC (1USSC is 150 mM NaCl plus 15 mM sodium citrate, pH
7.4) for Southern hybridization. RNA extract (10 Wg) was also trans-
ferred to a nylon membrane in 20USSC for Northern hybridization.
The PCR-ampli¢ed entire 3.8-kb LaMDR2 and 1.34-kb L. amazonen-
sis L-tubulin genes were used as probes [17]. Probes were labeled with
digoxigenin (DIG), hybridized to blots in a hybridization solution
(5USSC, 2% non-fat milk, 0.02% sodium dodecyl sulfate (SDS),
0.1% sarcosyl and 50% formamide) at 42‡C, and detected using a
DIG DNA labeling and detection kit (Boehringer-Mannheim, Mann-
heim, Germany). Messenger RNA was puri¢ed with Oligotex-dT30
column (Takara Bio, Tokyo, Japan) and subjected to reverse tran-
scription-PCR (RT-PCR). The sense primer (5P-CGACCGTTCGC-
CAGCTG-3P), the antisense primer (5P-GCCGGCCATTGCCA-
CAA-3P) and SuperScript One-Step RT-PCR system (Invitrogen)
were used for ampli¢cation of 337-bp DNA fragments from the
LaMDR2 mRNA.
2.5. Western blot analysis
Rabbit anti-LaMDR2 peptide antibodies were produced against a
synthetic peptide of 13 amino acids (DGEYKSRWELAQT), corre-
sponding to positions 1255^1267 of the COOH-terminus of LaMDR2
protein. Mouse anti-LaMDR2 recombinant antibodies were produced
by immunization of BALB/c mice with histidine-tagged recombinant
proteins puri¢ed from Escherichia coli, which were transfected with
pQE-32 (Qiagen) carrying a PCR product (LA10) corresponding to
136 amino acids of the NH2-terminal ABC region of LaMDR2. Wild-
type promastigotes and transfectants were harvested in di¡erent
growth phases: the early-log (EL), mid-log (ML), late-log (LL),
early-stationary (ES), and mid-stationary (MS) phase. Cells were lysed
in a sample bu¡er (50 mM Tris^HCl, 1% SDS, 20% glycerol and 1%
2-mercaptoethanol, pH 6.8) at 85‡C for 10 min. Each sample (equiv-
alent to 5U105 cells) was electrophoresed on 5^20% gradient SDS^
polyacrylamide gels. Proteins were transferred to a 0.22-Wm polyviny-
lidene di£uoride (PVDF) membrane and reacted with rabbit anti-
LaMDR2 peptide antibodies, mouse anti-LaMDR2 recombinant anti-
bodies, and rabbit anti-Leishmania surface membrane protein gp63
antibodies [23]. Mouse monoclonal antibody against chicken K-tubu-
lin was obtained from ICN Biomedicals (Aurora, OH, USA). The sera
were used at a 1:250^1000 dilution. Reactions were visualized with the
ECL-Plus Western Blotting Detection System on Hyper¢lms (Amer-
sham).
2.6. Transport study
Wild-type cells and transfectants in the ML, LL, and ES phase were
harvested. Cells were washed twice with a washing medium (15 mM
KCl, 10 mM (NH4)2SO4, 1 mM MgSO4 and 50 mM triethanolamine-
HCl, pH 6.9), and suspended in an incubation medium (15 mM KCl,
10 mM (NH4)2SO4, 1 mM MgSO4, 1 mM glucose and 50 mM tri-
ethanolamine-HCl, pH 6.9) at 25‡C [19]. The cells (1U107 cells/400
Wl) were incubated in the presence of 0.1 or 3 WM [3H]5-FU (37 MBq/
ml, Du Pont, France), and 1 or 3 WM [3H]vinblastine (9.25 MBq/ml,
Amersham) at 25‡C for up to 120 min. At several time points, cells
were ¢xed with 10% formaldehyde in ice-cold washing medium, and
washed four times with the washing medium. Cells were then lysed
with the lysis solution (Cell Culture Lysis Reagent, Promega) and
added with the scintillator solution. The radioactivity was measured
and accumulation of [3H]5-FU or [3H]vinblastine was expressed as
pmol/109 cells.
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3. Results
3.1. Homology of LaMDR2 to other ABC proteins
The open reading frame of the LaMDR2 gene encoded a
protein of 1267 amino acids, consisting of two similar halves,
each containing six putative transmembrane domains, Walker
A, motif C and Walker B (Fig. 1). LaMDR2 protein showed
no potential Asn-linked N-glycosylation sites at the putative
extracellular side. Alignment of deduced amino acid sequences
of LaMDR1 and LaMDR2 indicates that LaMDR2 has a
longer hydrophilic region between NH2-terminal Walker B
and the seventh transmembrane domain than LaMDR1
(Fig. 1). LaMDR2 showed 47% amino acid identity to
LaMDR1 [17], 29% to LtPGPA [18] and less than 40% to
ABC proteins in other species, including human MDR1
(ABCB1), human MDR3 (ABCB4), and Plasmodium falcipa-
rum mdr1 gene products (PGH-1).
3.2. Southern and Northern blot analysis of transfectants
The p6.5 vector contained anV7.5-kb Leishmania DNA, in
which the upstream p36 gene was replaced with a BamHI site
for cloning and the downstream nagt gene was kept as the
selective marker for tunicamycin [22]. The p6.5-LaMDR2/7
carried an insert V7-kb DNA fragment consisting of the
5P-£anking (V1.3 kb), coding (3.8 kb) and 3P-£anking
(V1.9 kb) regions of the LaMDR2 gene. Southern blot anal-
ysis indicated that the gene is present as a single copy (data
not shown). Based on the hybridization intensities against the
1.2-kb SalI fragments (arrowhead in Fig. 2A), the copy num-
bers of p6.5-LaMDR2/7 were estimated at approximately 13,
24 and 42 in cell lines maintained in the presence of tunica-
mycin at 10, 20 and 40 Wg/ml, respectively (Fig. 2A). By
Northern blot analysis, a major 7.2-kb and a minor 5.9-kb
LaMDR2 gene transcript were detected in total RNA samples
from these transfectants (Fig. 2B). Transfectants with p6.5-
LaMDR2/3.8, which carried only the PCR-ampli¢ed coding
region of the LaMDR2 gene, produced a major 5.2- and a
minor 7.4-kb LaMDR2 RNA (Fig. 2B). Although the corre-
sponding transcripts were hardly detected from wild-type cells
and transfectants with p6.5 by Northern blots, the LaMDR2
mRNAs were detected by RT-PCR (data not shown).
3.3. Expression of LaMDR2 proteins in transfectants
Total protein was extracted from promastigotes in di¡erent
growth phases and reacted with anti-LaMDR2 peptide anti-
bodies, which were raised against the COOH-terminal 13 ami-
no acids of LaMDR2 protein. The antibodies clearly recog-
nized a single protein of approximately 140 kDa in
transfectants with p6.5-LaMDR2/7, but hardly detected the
corresponding protein band in transfectants with p6.5 (Fig.
3A). The antibodies also detected LaMDR2 proteins in trans-
fectants with p6.5-LaMDR2/3.8, although the LaMDR2 ex-
Fig. 1. Comparison of the deduced amino acid sequences of LaMDR2 (DDBJ accession number AB008469) to LaMDR1 (DDBJ AB003329)
in L. amazonensis. Amino acids identical to LaMDR1 are indicated with dots. Twelve putative transmembrane domains, which are derived
from a computer prediction, are thickly underlined. Two other in-frame methionine translation start sites of LaMDR1 are indicated with aster-
isks. Walker A, Walker B and motif C are indicated with boxes.
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pression was gradually decreased in the following order: EL,
ML, LL, ES and MS phase (Fig. 3B). However, we found no
degradation of LaMDR2 proteins in these immunoblots.
Mouse anti-LaMDR2 recombinant antibodies, which were
raised against a recombinant protein of 136 amino acids in
the NH2-terminal ABC region of LaMDR2, also recognized a
protein of similar size in the same transfectant cell lines (data
not shown). Expression of gp63 surface membrane proteins
was slightly decreased in the stationary phase, whereas K-tu-
bulin was constitutively expressed regardless of the cell growth
phase (Fig. 3A,B).
3.4. Involvement of LaMDR2 in 5-FU resistance
The ED50 value against 5-FU was 2.5-fold higher (11.2 R 2.3
vs. 4.5 R 0.6 WM, P6 0.01) in transfectants with p6.5-
LaMDR2/7 than in transfectants with p6.5 (Table 1).
Although the degree of resistance was two- to three-fold,
the di¡erence was always observed and reproducible. No
cross-resistance was observed against the following com-
pounds: puromycin and doxorubicin as anticancer drugs,
Pentostam and amphotericin B as anti-leishmanial drugs,
chloroquine, me£oquine and artesunate as anti-malarial re-
agents, formycin B and tubercidin as nucleoside analogues,
and CdCl2. Unexpected hypersensitivities were observed
with respect to sodium arsenite and vinblastine (Table 1).
We veri¢ed that the LaMDR2 gene alone was su⁄cient to
confer 5-FU resistance, since the ED50 value of 5-FU was
9.5^11.5 WM in transfectants with p6.5-LaMDR2/3.8, which
Fig. 2. Southern and Northern blot analyses of transfectants with
the LaMDR2 gene. Total DNA was isolated from wild-type cells,
transfectants with p6.5 maintained in the presence of tunicamycin at
40 Wg/ml, and transfectants with p6.5-LaMDR2/7 maintained in the
presence of tunicamycin at 10, 20 or 40 Wg/ml. The DNA samples
were digested with SalI, electrophoresed on 0.8% agarose gel, trans-
ferred to a nylon membrane and hybridized with the DIG-labeled
LaMDR2 gene probe (A). The arrowhead in A indicates the hybrid-
ization signals to the 1.2-kb SalI DNA fragment. Total RNA was
isolated from the same cell lines and in addition from transfectants
with p6.5-LaMDR2/3.8 maintained with tunicamycin at 20 Wg/ml.
The RNA samples were electrophoresed on 0.8% RNA agarose gel,
transferred to a nylon membrane and hybridized with DIG-labeled
L-tubulin gene or LaMDR2 gene probe (B).
Fig. 3. Western blot analysis of LaMDR2 expression in transfec-
tants with the LaMDR2 gene. Promastigotes were harvested from
transfectants with p6.5, p6.5-LaMDR2/7 and p6.5-LaMDR2/3.8 in
the EL, ML, LL, ES and MS growth phases. Each cell lysate equiv-
alent to 5U105 was electrophoresed on a 5^20% gradient polyacryl-
amide gel and transferred to a PVDF membrane. The membrane
was immunostained with rabbit anti-LaMDR2 peptide antibodies,
mouse anti-chicken K-tubulin monoclonal antibodies, or rabbit anti-
Leishmania gp63 antibodies. Reactions were visualized with the
ECL-Plus chemiluminescence system.
Table 1
Drug susceptibility of L. amazonensis overexpressing LaMDR2
Drug ED50a Relative drug Resistanceb
p6.5 (n) p6.5-LaMDR2/7 (n)
Sodium arsenite (WM) 6.0R 1.6 (4) 4.2R 0.8 (4) 0.70*
Puromycin (WM) 1.9R 0.3 (6) 2.0R 0.5 (3) 1.05
Vinblastine (WM) 7.8R 0.6 (3) 5.0R 0.9 (3) 0.64**
Doxorubicin (WM) 1.40R 0.05 (3) 1.71R 1.1 (3) 1.24
Amphotericin B (Wg/ml) 3.4 R 0.7 (3) 3.2R 0.2 (3) 0.94
Pentostam (mg/ml) 220R 59 (5) 222R 20 (3) 1.01
5-FU(WM) 4.5R 0.6 (8) 11.2R 2.3 (6) 2.50**
Chloroquine (WM) 13.3R 3.9 (3) 13.8R 1.3 (3) 1.04
Me£oquine (Wg/ml) 1.3 R 0.5 (5) 1.3R 0.4 (3) 1.00
Artesunate (WM) 19.7R 13.3 (3) 23.5R 8.5 (3) 1.18
CdCl2 (nM) 113R 30 (3) 99R 34 (3) 0.88
Formycin B (nM) 104R 17 (4) 93R 11 (3) 0.89
Tubercidin (nM) 155R 51 (4) 146R 31 (4) 0.94
Signi¢cance: *P6 0.05; **P6 0.01.
aThe ED50 value is the meanRS.D. of three to eight independent experiments.
bRelative drug resistance is the ratio of the p6.5-MDR2/7 ED50 divided by the p6.5 ED50.
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contained only the PCR-ampli¢ed coding region of the
LaMDR2 gene.
3.5. Decreased accumulation of 5-FU in transfectants
overexpressing LaMDR2
We examined the uptake and accumulation of [3H]5-FU in
transfectants in di¡erent growth phases. We used two di¡erent
5-FU doses, 3 WM and 0.1 WM. The former dose was just
below the ED50 value of wild-type cells and transfectants
with p6.5, and the latter concentrations showed no e¡ects
on cell growth. In transfectants with p6.5, 5-FU accumulation
was continually increased up to 120 min, regardless of the cell
growth phases and the drug concentrations (Fig. 4A^D). In
contrast, in transfectants with p6.5-LaMDR2/7 in the ML
phase, 5-FU uptake was 1.5-fold greater than that in control
transfectants in the ¢rst 30 min, and the drug accumulation
was gradually decreased to 20^30% of the control level at 90
min at both drug concentrations (Fig. 4A,C). Although this
initial increase of drug accumulation was not observed in the
LL phase cells, the drug accumulation was also markedly
decreased at both drug concentrations (Fig. 4B,D). However,
when cells from the ES phase were used, 5-FU accumulation
was continually increased in both transfectants with p6.5 and
p6.5-LaMDR2/7 up to 120 min, and no di¡erence was found
in the accumulation kinetics between these transfectant cell
lines (data not shown). In addition, accumulation of
[3H]vinblastine was similarly increased up to 120 min in
both transfectant cell lines regardless of the growth phase,
suggesting that overexpression of LaMDR2 was speci¢c to a
decreased accumulation of 5-FU (data not shown).
4. Discussion
In the present study, we isolated and characterized a novel
ABC protein, LaMDR2, in the protozoan parasite Leishma-
nia. Putative LaMDR2 had a typical MDR structure, but
exhibited only 47% amino acid identity to its most closely
related protein, LaMDR1, which was recently isolated from
the same species [17]. Promastigotes that overexpressed
LaMDR2 showed signi¢cant resistance to 5-FU, but not to
Leishmania MDR1 substrates, such as vinblastine, puromycin
or doxorubicin [15^17]. In addition, transfectants with
LaMDR2 exhibited a reduced accumulation or active extru-
sion of 5-FU. These results clearly suggest that LaMDR2 is
structurally and functionally di¡erent from LaMDR1, and
represents a new member of the MDR (ABCB) subfamily of
leishmanial ABC proteins.
Overexpression of LaMDR2 conferred 5-FU resistance in
Leishmania promastigotes. This is the ¢rst report of a MDR
(ABCB) subfamily protein of ABC transporters causing 5-FU
resistance in eukaryotic cells. Human MRP1 of the ABCC
subfamily conferred 5-FU resistance in NIH 3T3 cells [24].
A variety of substrate speci¢city or functional diversity exists
for each ABC subfamily protein among di¡erent organisms
[8,9,11]. In Leishmania, two MDR (ABCB) subfamily genes
and ¢ve PGP (ABCC) subfamily genes have been character-
ized ([20], present study). Recently, the ¢rst leishmanial
ABCA subfamily protein was reported to be involved in phos-
pholipid tra⁄cking [14].
The subcellular localization of LaMDR2 proteins is un-
known, although our preliminary indirect immuno£uores-
cence studies showed that anti-LaMDR2 antibodies predom-
inantly stained the £agellar pocket and asymmetrical tubular
structure in the transfectants. The tubular structure may cor-
respond to the multivesicular tubule lysosome in Leishmania
[25^27]. The Plasmodium falciparum MDR protein (PGH-1) is
located in the food vacuole membrane and associated with
chloroquine resistance [28]. Studies on further immuno£uores-
cence and immunoelectron microscopy are under way to clar-
ify whether LaMDR2 is associated with the lysosomal mem-
brane. Alternatively, LaMDR2 may stimulate or regulate
other molecule(s), which enhance the uptake or export of
5-FU. A highly selective and high-a⁄nity Hþ-dependent
transporter for uracil was reported in procyclic forms of Try-
panosoma brucei brucei [29]. This uracil uptake was inhibited
by 5-FU, but not by a broad range of purine and pyrimidine
nucleosides and nucleobases, suggesting a nucleobase-Hþ-
symporter model for this carrier. It is unknown whether leish-
manial carrier-dependent nucleobase transporters are involved
in 5-FU uptake or export.
Finally, the physiological function of LaMDR2 remains to
be elucidated. Expression of LaMDR2 in wild-type promasti-
gotes was undetectable by Western blot analysis, although the
corresponding transcripts were detected by RT-PCR. Mam-
malian MDR2, the other member of the MDR subfamily, is
involved in the transport of long-chain phospholipids such as
phosphatidylcholine [12]. A daunomycin-resistant L. tropica
cell line, which overexpressed a P-glycoprotein-like transport-
er (probably LtMDR1), displayed signi¢cant cross-resistance
to miltefosine (alkyl-lysophospholipid or hexadecylphospho-
choline) [30], a new chemotherapeutic agent against visceral
leishmaniasis. However, we found no cross-resistance to mil-
tefosine in transfectants with p6.5-LaMDR2/7 (unpublished
data). Further studies are required to determine if LaMDR2
transports lipid molecules.
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(Hokkaido University), S. Kawazu (International Medical Center of
Japan) and K. Ueda (Kyoto University) for helpful suggestions.
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